Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673992 | 0.88 | HSD11B1 (0.42) | HSD11B1L3MBTL1MTNR1AMTNR1BCCR9 | |
| SCHEMBL21490334 | 0.85 | L3MBTL1 (0.52) | NR1H2L3MBTL1MTNR1AMTNR1BCCR9 | |
| SCHEMBL29443054 | 0.85 | L3MBTL1 (0.52) | NR1H2L3MBTL1MTNR1AMTNR1BCCR9 | |
| SCHEMBL2813774 | 0.82 | NOD2 (0.40) | NR1H2HSD11B1NR1H3 | |
| SCHEMBL20494501 | 0.81 | S1PR2 (0.41) | NR1H2L3MBTL1MTNR1AMTNR1BNR1H3 | |
| SCHEMBL30071190 | 0.81 | S1PR2 (0.41) | NR1H2L3MBTL1MTNR1AMTNR1BNR1H3 | |
| SCHEMBL3027093 | 0.79 | CA12 (0.42) | NR1H2L3MBTL1MTNR1AMTNR1BCCR9 | |
| SCHEMBL19013607 | 0.79 | NR1H2 (0.45) | NR1H2L3MBTL1CCR9 | |
| SCHEMBL3024003 | 0.79 | NR1H2 (0.45) | NR1H2L3MBTL1NR1H3 | |
| SCHEMBL18989603 | 0.78 | PTGS2 (0.43) | NR1H2L3MBTL1CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2170072-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249179-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H2 3/4885HSD11B1 105/4885L3MBTL1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.